AGIO Agios Corp: Price-to-Projected Revenue Ratio

Agios Pharmaceuticals - graphic logo of issuer AGIO

Current revenues for Agios Pharmaceuticals are based on the sale of innovative treatments for hemolytic anemia, although long-term potential is driven by management's strategic optimization of the metabolic portfolio. The business's forward P/S visualizes this balance, with the metric holding at 13.40. Development is further complemented by the implementation of robotic genetic screening and predictive data analysis software.

Agios Pharmaceuticals, Inc. - AGIO Market Cap to Expected Sales Ratio (period 07/04/2022 - 11/14/2026)

Summary analytical data breakdowns for Agios Corp (AGIO)

- market price and analyst price targets:
Price Chart Agios Pharmaceuticals, Inc.|AGIO - Average Forecast Price
- company stock capitalization data:
Market Value Agios Corp|AGIO - Total Company Value
- book value of equity indicators:
Book Value per Share Agios Pharmaceuticals|AGIO - Book Valuation of Business|Market Value to Book Value Ratio agios.com|AGIO - Company Total Asset Base
- business debt structure and liquidity details:
Debt to Equity Agios Pharmaceuticals|AGIO - Long-Term Debt to Equity Ratio|Short-Term Debt to Capital Agios Pharmaceuticals|AGIO - Company Aggregate Debts|Debts to Book Capitalization Agios Corp|AGIO - Long-Term Indebtedness|Company Short-Term Debts Agios Pharmaceuticals|Quick Liquidity agios.com
- financial results and valuation multiples details:
AGIO - Company Net Income|Expected Profit Agios Pharmaceuticals|AGIO - Business Payback Period|Projected Price to Earnings Agios Pharmaceuticals Inc|AGIO - Growth-Adjusted Payback Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Agios Corp|AGIO - Profit before deduction of interest, taxes, depreciation and amortization|Net earnings per share (EPS TTM) Agios Pharmaceuticals|AGIO - Earnings per share for the trailing year|Quarterly EPS earnings growth agios.com|AGIO - Earnings growth in current year|Net earnings per share growth forecast for next year Agios Pharmaceuticals
- sales volume and revenue indicators:
AGIO - Company Sales Revenue|Company Projected Revenue Agios Pharmaceuticals, Inc.|AGIO - Market Cap to Revenue|Forward P/S Multiple Agios Corp
Fundamental company analysis:Agios Pharmaceuticals, Inc. AGIO
Original product of Agios Corp

Finding a balance between operational risks and return on capital at Agios Pharmaceuticals (AGIO) requires an assessment of the effectiveness of strategic partnerships for the development of orphan drugs. The forward P/S ratio reflects the company's market value relative to projected revenue, allowing investors to filter out market noise and determine a fair valuation multiple for the business based on its long-term growth potential.

Main competitors

Price-to-Projected Revenue Ratio Ascendis Pharma ASND|Madrigal Pharmaceuticals Inc (MDGL) - Market Cap to Future Revenue Ratio|CORT - Price-to-Projected Revenue Ratio|RYTM: Price-to-Projected Revenue Ratio|AKRO: Forward P/S Multiple|MTSR - Market Cap to Expected Sales Ratio|Price-to-Projected Revenue Ratio MoonLake|Crinetics Pharmaceuticals, Inc. (CRNX) - Market Cap to Expected Sales Ratio|Price-to-Projected Revenue Ratio NewAmsterdam Pharma N.V. (NAMS)|Forward Price-to-Revenue Multiple Soleno Therapeutics Corp SLNO|Forward P/S Multiple FOLD (Amicus Therapeutics)|Forward P/S Multiple 89bio.com ETNB|Structure Therapeutics Inc. - Forward P/S Multiple|Projected Price to Revenue MiMedx Group Inc (MDXG)|RZLT: Forward P/S Multiple|LXRX - Market Cap to Expected Sales Ratio|Price-to-Projected Revenue Ratio MBX Biosciences Inc|Market Cap to Future Revenue Ratio altimmune.com ALT|Price-to-Projected Revenue Ratio Aardvark Therapeutics (AARD)|Market Cap to Expected Sales Ratio Sagimet Biosciences, Inc.|BioAge Labs Inc. - Forward Price-to-Revenue Multiple|Forward Price to Sales BMEA|QNCX - Price-to-Projected Revenue Ratio|Future Price to Revenue GUTS|VTVT: Forward P/S Multiple|Agape ATP - Forward Price to Sales|PLUR (Pluristem Therapeutics) - Forward P/S Multiple|Forward P/S Multiple Synlogic Corp|Price-to-Projected Revenue Ratio Lipocine Inc. (LPCN)|MTNB (matinasbiopharma.com) - Forward Price to Sales|Price-to-Projected Revenue Ratio Spruce Biosciences, Inc. SPRB|GLTO - Forward Price-to-Revenue Multiple|Carmell Corp - Forward P/S Multiple|LUMO - Forward P/S Multiple|ONVO: Forward P/S Multiple|Forward Price-to-Revenue Multiple radiuspharm.com